Young T Cell Expansion for Adoptive Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adoptive cell therapy using tumor-reactive T-cells faces technical, regulatory, and logistic challenges due to complex cell processing and in vitro lymphocyte culturing requirements, necessitating improved methods for cancer treatment.
Innovation Solution
A method involving culturing autologous T cells, expanding them using OKT3 antibody, IL-2, and feeder lymphocytes, enriching for CD8+ T cells, and administering nonmyeloablative lymphodepleting chemotherapy followed by expanded T cells that are 19 to 35 days old, without prior screening for specific tumor reactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tumor-reactive T-cells are used for adoptive cell therapy, then cancer treatment effectiveness is improved, but technical complexity and processing requirements increase
Solution Approach 1:
The patent segments the T-cell population by age, separating young T-cells (less than 35 days in culture) from older T-cells. This segmentation allows the therapy to focus on young T-cells that have not undergone extensive in vitro culturing, thereby reducing processing complexity while maintaining treatment effectiveness.
Solution Approach 2:
The patent performs preliminary selection of young T-cells before expansion and administration. By identifying and isolating young T-cells early in the process (less than 35 days in culture), the method avoids the need for complex screening and processing that would be required for older, more differentiated T-cells.
2Quantity of substance
If extensive in vitro lymphocyte culturing is performed, then T-cell expansion is achieved, but treatment time and costs increase
Solution Approach 1:
The patent performs preliminary identification and selection of young T-cells (less than 35 days in culture) before expansion. This preliminary action ensures that the starting population has high proliferative capacity, allowing for rapid expansion and reduced overall treatment time compared to starting with older T-cells.
Solution Approach 2:
The patent changes the key parameter of T-cell age/culture duration, selecting cells that are less than 35 days in culture. This parameter change fundamentally alters the proliferative potential and expansion kinetics of the T-cells, enabling faster treatment timelines while achieving sufficient cell quantities.
3Measurement precision
If T-cells are screened for specific tumor reactivity, then treatment specificity is improved, but processing complexity and time increase
Solution Approach 1:
The patent extracts the requirement for complex in vitro tumor reactivity screening by selecting young T-cells (less than 35 days in culture) that have not been extensively cultured. The rationale is that young T-cells retain endogenous tumor reactivity without requiring artificial activation or expansion that would necessitate complex screening protocols.
Solution Approach 2:
The patent uses young T-cells that are essentially 'disposable' in the sense that they are used in their native, uncultured state without requiring expensive and time-consuming screening processes. The young age of the cells themselves serves as the selection criterion, eliminating the need for complex functional assays.
4Quantity of substance
If T-cells are cultured for extended periods, then cell expansion is achieved, but cell functionality and antitumor activity decrease
Solution Approach 1:
The patent performs preliminary selection of young T-cells (less than 35 days in culture) that have not undergone extended culturing. This preliminary action preserves the cells' native functionality and antitumor activity while still allowing for necessary expansion to therapeutic doses.
Solution Approach 2:
The patent changes the culture duration parameter to less than 35 days, which fundamentally preserves T-cell functionality and antitumor activity. This parameter change prevents the functional deterioration that occurs with extended in vitro culturing while still enabling sufficient cell expansion for therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances in vivo proliferation and antitumor activity of T cells, reduces treatment time and costs, and allows for broader use of adoptive cell therapy by eliminating the need for in vitro antigen reactivity testing, thereby improving cancer regression in mammals.
Implementation Method 1
expanding the cultured T cells using OKT3 antibody, IL-2, and feeder lymphocytes
Implementation Method 2
administering to the mammal nonmyeloablative lymphodepleting chemotherapy
Data Source
AI summary
The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.